Showing results (61-70 of 535) with videos related to

Sort By:
Pageof 54
Blood Cells|January 1, 1988
In vitro and in vivo action of recombinant human GM-CSF (rhGM-CSF) in patients with myelodysplastic syndromesD Hoelzer, A Ganser, B Völkers, et al.
European Cytokine Network|May 1, 1991
In vivo administration of recombinant human interleukin-3 elicits an acute phase response involving endogenous synthesis of interleukin-6A Lindemann, A Ganser, D Hoelzer, et al.
Experimental Hematology|May 1, 1989
Inhibitory effect of azidothymidine, 2'-3'-dideoxyadenosine, and 2'-3'-dideoxycytidine on in vitro growth of hematopoietic progenitor cells from normal persons and from patients with AIDSA Ganser, J Greher, B Völkers, et al.
Experimental Hematology|October 12, 2000
Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromesU Kalina, W K Hofmann, S Koschmieder, et al.
Blut|April 1, 1984
Low-dose Ara-C in the treatment of acute leukemia. Cytotoxicity or differentiation induction?D Hoelzer, A Ganser, B Anger, et al.
Behring Institute Mitteilungen|August 1, 1988
Phase I/II study with GM-CSF in patients with myelodysplastic syndromesD Hoelzer, A Ganser, J Greher, et al.
Experimental Hematology|May 30, 2001
Transforming growth factor-beta1 interferes with thrombopoietin-induced signal transduction in megakaryoblastic and erythroleukemic cellsU Kalina, S Koschmieder, W K Hofmann, et al.
Experimental Hematology|March 25, 1999
Characterization of defective megakaryocytic development in patients with myelodysplastic syndromesW K Hofmann, U Kalina, S Wagner, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|June 26, 2007
Genomic imprinting of insulin-like growth factor 2 (IGF-2) in chronic synovitisB Möller, G Kerschbaumer, M Komor, et al.
Annals of Hematology|June 10, 1998
Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicinG Seipelt, W K Hofmann, H Martin, et al.
Pageof 54